Lori Leslie, MD, and Robert Figlin, MD, discuss the latest drugs and clinical trial data on CLL treatment. Dr. Leslie shares her strategy for sequencing agents, including various BTK inhibitors and venetoclax, and how she decides on treatment in patients whose disease progresses or are refractory.